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Purpose of review: This decade has seen a resurgence of yellow fever (YF) that has also 
affected travelers with a record number of international travelers infected by YF virus 
including the first documented importation of YF into Asia.   
Recent findings: The recent resurgence of YF has been attributed largely to sub-optimal 
vaccination coverage along with waning population-level immunity. With increasing YF 
cases in travelers, travel medicine providers need to familiarize themselves with the diagnosis 
and clinical management of severe YF.  reinforce the generally acceptable safety profile of 
YF vaccine, but highlight the importance of continued physician and traveler education 
regarding the risks and benefits of YF vaccination, particularly for older travelers. There is an 
urgent need to better define “significant and unavoidable risk” for better benefit-risk 
assessments.  
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Introduction 
Yellow fever is an old-age scourge, and one of the arboviral diseases associated with the 
highest case fatalities[1]. This decade has seen a resurgence of yellow fever (YF) that has also 
affected travelers with a record number of international travelers infected by YF virus 
returning to Europe and the US[2].  End 2015 to mid 2016, Angola experienced its biggest 
yellow fever outbreak for decades that rapidly spread via mobility networks within the 
country and to neighboring nations[3].  Towards the end of 2016, YF outbreaks emerged in 
close proximity to the most populated areas of metropolitan São Paulo and Rio de Janeiro in 
Brazil, thus posing an all-time high risk for rapid global spread via air travel. Health care 
professionals from non-endemic countries are therefore increasingly likely to see travelers 
with yellow fever. Here we review the risk of yellow fever in travelers, clinical management, 




Yellow fever is an acute infectious disease caused by the yellow fever virus, a flavivirus 
transmitted in tropical or subtropical areas, mainly through the bite of infected Aedes spp 
mosquitoes. YF is currently reported or has been reported in 34 countries in tropical Africa 
and 13 countries in the Americas, with sub-Saharan Africa carrying about 90% of the overall 
burden. Official reports of yellow fever incidence grossly underestimate the true number of 
cases, first of all because surveillance is based on the case definition of “fever and jaundice”, 
but jaundice is not frequent even in severe yellow fever cases[4]; second, in many countries 
no surveillance systems exist, and third, a large proportion of yellow fever infections can be 
asymptomatic or mildly symptomatic, and difficult to differentiate clinically from other 
febrile illnesses in countries with limited resources for laboratory confirmation.  
The recent resurgence of YF has been attributed largely to sub-optimal vaccination coverage 
along with waning population-level immunity[5]. Overall, substantial increases in YF vaccine 
coverage have occurred since 1970, but notable gaps still exist in coverage within risk zones, 
with around 400 million people still requiring vaccination in areas with YF virus transmission 
to achieve the 80% population coverage threshold recommended by WHO. The resulting gaps 
in YF vaccination coverage affect between 43% and 52% of the population within yellow 
fever risk zones[5, 6]. Lack in harmonized YF maps and the changing epidemiology of YF 
led to a collaborative WHO and CDC initiative in 2008-2010 to develop criteria and 
systematically apply such criteria for the designation of risk and specific changes to the 
classification of areas with risk of transmission of YF virus[7]. Four levels of YF risk were 
outlined and geographical areas were classified into the following categories: endemic, 
transitional, low potential for exposure, and no risk. 
 
Risk in travelers 
More than 9 million people from non-endemic countries in Asia, Europe, and North America 
travel to countries where YF is endemic, and these numbers are likely to increase given the 
increasing travel volumes globally[8]. Unvaccinated travelers who visit areas in Africa during 
periods of epidemic activity have an estimated risk of 1 in 267 and risk of death of 1 in 1333, 
although the risks are considerably lower during inter-epidemic periods[9]. Risk of illness and 
death for individuals travelling to South America is thought to be about ten times lower than 
it is for those travelling to Africa, because the lower rate of transmission in the jungle cycle in 
the Americas[9]. 
In recent years, the number of travelers importing yellow fever virus to non-endemic 
countries is at a record high[10].  Eleven unvaccinated Chinese working in Angola were 
infected with YF virus and exported the virus to China; the first documented exportation of 
yellow fever via travelers to Asia[11]. Between January 2018 and December 2018, 10 travel-
related cases of yellow fever, including four deaths, were reported in unvaccinated 
international travelers returning from Brazil[2]. Since then, two further cases were reported 
through GeoSentinel (GeoSentinel Director Dr David Hamer, personal communication). 
GeoSentinel is a global network of travel medicine providers that see ill returned 
travelers[12], and it set up to assess destination specific risks[13], risks by purpose of 
travel[14-17], and by diseases[18-22] and time trends[23].  Yellow fever was not reported in a 
descriptive analysis of life-threatening tropical diseases among 82,825 ill western travelers 
reported to GeoSentinel from June of 1996 to August of 2011[24].  Travelers’ risk of 
acquiring YF is difficult to predict due to seasonal and epidemic variations, short duration of 
travel, ecologic determinants of virus transmission, immunity profiles, and activities. Overall 
however, the incidence of YF in travelers is very low, lower than most other vaccine-
preventable travel related diseases [24-26], also because many travelers are protected through 
YF vaccination.  
 
 
Clinical manifestations and clinical management 
Clinical symptoms usually appear 3–6 days after a bite from an infected mosquito. YF virus 
first replicates in the site of inoculation, after which it spreads to the lymph nodes. It then 
travels to the liver, spleen, bone marrow, kidneys and myocardium but rarely spreads to the 
brain, exhibiting viscerotropic affinity. Typically, the disease onset is abrupt, with fever, 
muscle pain, particularly backache, headache, shivering, loss of appetite, and nausea or 
vomiting. Congestion of the conjunctivae and face are common, as well as relative 
bradycardia in the presence of fever[27]. In approximately 15% of infected persons, the 
illness recurs in more severe form after a brief remission of 2–24 hours[27]. YF can be a 
treacherous disease as its initial clinical presentation may be quite benign and non-specific, 
but can then take a fulminant course within a matter of a few days[28]. Clinicians need to be 
highly suspicious of YF, as earlier diagnosis may result in better management of this life-
threatening disease.   
Treatment of uncomplicated yellow fever is based on supportive clinical management. In 
mild disease, paracetamol is used to treat the symptoms of fever, myalgia and back pain and 
the patient can be managed at home. Salicylates and non-steroidal antiinflammatory drugs 
should be avoided because of the risk of gastrointestinal bleeding and platelet suppression.  
Risk factors for developing more severe yellow fever include older age, high AST levels[29] 
and high neutrophil counts and YF viral load[30]. In the experience of the intensive care of a 
tertiary hospital in Sao Paolo, Brazil, during the recent YF outbreak, the fatality rate was 
67%[4]. Patients with diabetes mellitus had a higher case fatality rate (CFR) of 80%, although 
the difference was not significant due to the small sample size[4]. Leading causes of death 
were severe gastrointestinal bleeding, epileptic status, severe metabolic acidosis, pancreatitis, 
and multi-organ failure[4]. The following management lessons for severe YF were learnt 
from the Brazilian experience: Anticonvulsant drugs in patients with any symptoms of hepatic 
encephalopathy or arterial ammonia levels>70 µmol/L should be commenced, and therapeutic 
doses of intravenous proton pump inhibitors should be administered to present 
gastrointestinal bleeding. Other new therapy recommendations include early institution of 
plasma exchange[4].  
 
Diagnosis 
YF is difficult to diagnose clinically, especially during the early stages of the febrile disease. 
The differential diagnosis is wide and includes dengue[31], malaria, leptospirosis, viral 
hepatitis, and other haemorrhagic fevers. Incubation time and epidemiological clues are 
needed to raise the suspicion and request for laboratory confirmation. During the first days of 
illness, the diagnosis can be made by reverse transcriptase polymerase chain reaction (RT-
PCR).  However, laboratory diagnosis of YF is generally accomplished by testing serum to 
detect virus-specific IgM and neutralizing antibodies. A positive serological test for YF IgM 
is not sufficient to confirm a case[27]. If a person suspected of having YF tests positive for 
YF IgM, serology for other common flaviviruses should be carried out. Neutralizing antibody 
levels should be confirmed by using the plaque reducation neutralization test (PRNT), a more 
specific test for YF[32]. A history of recent vaccination needs to be taken into account when 
interpreting the results of YF testing. On 31 July 2018, the Centers for Disease Control 
(CDC) and WHO launched a trial version of a new ELISA test which is simpler and faster to 
perform. The new kit, called ELISA YF MAC HD, developed by CDC, ensures a 
standardized platform for yellow fever IgM testing, shortens the turnaround time from 2 days 
to just 3.5 h, but does not overcome the cross-reactivity issues with other flaviviruses[33].  
 
Yellow Fever Vaccine 
All currently YF vaccines are live attenuated viral vaccines from the 17D lineage based on a 
wild-type YF virus isolated in Ghana in 1927, developed more than 80 years ago by empirical 
passage in tissue culture, principally chicken embryo. The attenuated vaccine virus exists in 2 
sub-strains (17D-204 and 17DD) which share 99.9% sequence homology[27]. Both sub-
strains are used in vaccines prepared by culturing the virus in embryonated eggs, which is the 
main reason why YF vaccines are not rapidly scalable during an outbreak. The vaccine 
contains sorbitol and/or gelatine as a stabilizer and is lyophilized, without a preservative. 
Lyophilized vaccine should be stored and kept at 2–8 °C and reconstituted immediately 
before use with the sterile diluent provided by the manufacturer. After reconstitution, most 
YF vaccines should be kept on ice, protected from sunlight, and discarded after 1–6 hours. YF 
vaccines are given as a single dose (0.5 ml) either subcutaneously or intramuscularly. 
Currently there are five manufacturers: Sanofi Pasteur (for the North American and European 
market), Institut Pasteur in Senegal, Tiantan in China, Bio-Manguinhos/Fiocruz in Brasil, and 
–chukaov Institue in Russia. Only four manufacturers are WHO pre-qualified: Bio-
Manguinhos, Institut Pasteur, Chumaov Institute and Sanofi Pasteur (Europe).  
About 80%–100% of vaccine recipients develop protective levels of neutralizing antibodies 
within 10 days and 99% do so within 30 days[27]. Interestingly, no formal human efficacy 
studies have been performed with YF vaccine, however, 80 years of experience with ore than 
600 million doses given attest to an extremely high efficacy. The systematic review that was 
the bases for WHO`s grading table[34] showed that since the introduction of YF vaccination 
in the 1930s, and following the administration of >540 million doses of vaccine since then, 
only 12 suspected cases of YF disease post vaccination have been identified[35]. 
 
Serious adverse events to Yellow Fever Vaccination 
YF vaccines have been available since the 1930s, and are generally considered safe and 
effective. Of 666 respondents in a travel medicine clinic in Germany, 370 (55.6%) reported 
AEs, of which 258 (38.7%) were systemic and 230 (34.5%) were local. No severe AEs 
associated with YF vaccination were reported. Elderly vaccinees (aged >/=60 years) reported 
fewer total AEs than those aged <60 years (42.9% vs 60.3%;P < 0.001)[36]. However, reports 
on serious adverse reactions with severe clinical outcomes and even deaths emerged in the 
endemic population and travelers since 2001[37-39]. Yellow fever vaccine-associated 
viscerotropic disease (YEL-AVD) is a rare and serious adverse event of the yellow fever (YF) 
vaccine that mimics wild-type YF[37, 38]. The pathomechanism is poorly understood, but is 
likely not due to the impaired magnitude of adaptive immunity but instead to anomalies in the 
innate immune system and a possible disruption of the CCR5-RANTES axis[40]. Age and 
thymus dysfunction appear to be the main risk factors for YEL-AVD.  Age-related regression 
of the thymus is associated with a decline in naive T cell output. This is thought to contribute 
to the reduction in T cell diversity seen in older individuals and linked with increased 
susceptibility to infection[41]. Autosomal recessive, complete IFNAR1 deficiency was also 
shown to result in life-threatening complications of vaccination with live attenuated measles 
and YF viruses in previously healthy individuals[42]. Adverse events following YF 
vaccination reported to the U.S. Vaccine Adverse Event Reporting System (VAERS) from 
2007 through 2013 including age- and sex-specific reporting rates of all SAE, anaphylaxis, 
YF vaccine-associated neurologic disease (YEL-AND) and YF vaccine-associated 
viscerotropic disease (YEL-AVD) highlighted the following[43]: There were 938 adverse 
events following YF vaccination; of these, 84 (9%) were classified as SAEs for a rate of 3.8 
per 100 000 doses distributed. Reporting rates of SAEs increased with increasing age with a 
rate of 6.5 per 100 000 in persons aged 60-69 years and 10.3 for >/=70 years. The rate for 
anaphylaxis was 1.3 per 100 000 doses distributed and was highest in persons </=18 years 
(2.7 per 100 000). Reporting rates of YEL-AND and YEL-AVD were 0.8 and 0.3 per 100 
000, respectively; both rates increased with increasing age.  These findings underpin the 
importance of continued physician and traveler education regarding the risks and benefits of 
YF vaccination, particularly for older travelers. YEL-AVD only occurs after primary 
vaccination. 
Neurotropic serious averse reactions (YEL-AND) have been better characterized since 2001 
with the development of case definitions, but have been known from 1950s in children 
younger than 9 months of age, an observation which led to the age restriction. YEL-AND is 
considered a collective group of clinical syndromes, and can be due to direct viral invasion of 
the central nervous system resulting in encephalitis or meningitis, or be due to a peripheral 
autoimmune complex (resulting in Guillain Barre Syndrome, acute disseminated 
encephalomyelitis or myelitis), or it can be due to a combination of both direct viral and 
autoimmune response. Risk factors are young and older age, although –unlike YEL-AVD, a 
greater proportion of cases have been in younger adults and those without obvious risk 
factors, hence, YEL-AND is more difficult to predict.  
Limited data on the use of YF vaccination during pregnancy are available, and are usually 
derived from reports where pregnant women were either inadvertently vaccinated or given the 
vaccine during outbreaks. Two studies found no increased risk of major malformations or 
fetal death[44, 45]. However, an earlier study suggested a higher rate of spontaneous 
abortions with a relative risk of 2.3 among 39 pregnant women who received the vaccine 
[46]. HlV-infected patients with a CD4+ count > 200 cells/mm3 do not have increased risk of 
AEs from YFV[47]. Safety of live vaccines in immmunocompromised travelers other than 
HIV is of particular interest. In one Swiss study, of 197 immunocompromised travelers 92 
had received the YF vaccine, but reassuringly the incidence of systemic and local reactions 
were the same as when administered in healthy controls[48]. Some argue that we are possibly 
erring on the side of caution and under-vaccinating travelers who would benefit from YF 
vaccination[49]. Egg allergy vaccination protocols seem to provide a safe way to immunize 
patients with egg allergy[47].  
 
Co-administration with other travel vaccines 
Compact and short pre-travel immunization schedules, which include several vaccinations in 
a single visit, are desirable for many travelers[50]. However, concomitant vaccination could 
potentially compromise immunogenicity and/or safety of the individual vaccines and, 
therefore, possible vaccine interferences should be carefully assessed. Interference is 
particularly of concern for two live vaccines. Given the current measles resurgence[51, 52] 
that may necessitate offering measles vaccination to adult travelers and migrants[53-56] who 
may also require YF vaccine demands more guidance on whether such vaccines can be co-
administered on the same day or whether 28 days interval should be observed. Geometric 
mean titres for yellow fever were approximately three times higher among those who 
received MMR vaccinations 30 days later compared to concurrent administration of MMR 
and YF in a study in Brazil, suggesting that MMR and yellow fever vaccines should not be 
given on the same day[57].  In a phase 4, randomised, non-inferiority trial in Gambia infants 
aged 9-10 months who were randomly assigned to receive the IPV, measles-rubella, and 
yellow fever vaccines, singularly or in combinationshowed that YF antibody titres were 
reduced by co-administration but the seroconversion rates achieved non-inferiority [58]. 
Concurrent co-administration with inactivated vaccines is less of a problem. A recent study 
provided evidence that MenACWY-CRM can be administered with typhoid Vi 
polysaccharide vaccine and live attenuated YF vaccine without compromising antibody 
responses stimulated by the individual vaccines(NCT01466387)[59].  
 
Duration of Protection, and controversies about the need for booster doses 
In April 2013, the Strategic Advisory Group of Experts (SAGE) on immunization stated that 
a single dose of yellow fever (YF) vaccine is sufficient in the general population to confer a 
lifelong protection against YF. As the period of validity of the International Certificate of 
Vaccination (ICV) was extended to a lifetime in June 2016, no booster dose are officially  
needed. The rationale for this recommendation was based.on a systematic review by Gotuzzo 
et al which identified 6 studies indicating that a high proportion of vaccine recipients (>90%) 
have detectable levels of serum neutralizing antibodies up to 20 years post YF 
vaccination[35]. In 2015, the Advisory Committee on Immunization Practices (ACIP) in the 
US voted that a single primary dose of yellow fever vaccine provides long-lasting protection 
and is adequate for most travelers. ACIP also approved recommendations for at-risk 
laboratory personnel and certain travelers to receive additional doses of yellow fever vaccine. 
However, Amanna and Slifka argued based on epidemiological data on vaccine failures 
(particularly evident at >10 years after vaccination) that current recommendations to no 
longer administer YFV-17D booster vaccination should be carefully re-evaluated[60].  
Seroconversion rates in infants aged 9 months are clearly lower than in adults, and this fact 
would suggest a booster dose at least 10 years later for those who received YF vaccination at 
the age of 9 months[61]. Few studies have assessed the duration of humoral immunity 
following yellow fever (YF) vaccination in a non-endemic populations such as travelers. A 
recent CDC study on the persistence of neutralizing antibodies to YF among 234 US travelers 
showed that among the 155 individuals vaccinated who were vaccinated <10 years prior to 
serum collection, 146 (94%) had a positive PRNT compared with 82% (54/66) of individuals 
vaccinated >/=10 years prior to serum collection (P = 0.01)[62]. Post-vaccination PRNT titers 
showed a time-dependent decrease. Individuals with immune-compromising conditions were 
less likely to have a positive PRNT (77%) compared with those who were not immune-
compromised (92%; P = 0.04) [62]. This study triggered several editorials and letters to the 
editor in the Journal of Travel Medicine arguing for two life-time doses[63, 64] versus 
following the WHO recommendations for one life time dose in travelers[65]. A booster dose 
could be considered for certain travelers with risk factors, persons living with HIV or other 
immuncoompromising conditions who are planning travel to high-risk areas based on 
immune competence and time since vaccination. 
A prospective study determined the potential impact of the SAGE recommendations on the 
vaccination activity of travel clinics. The authors showed that among 1,037 subjects seen in 
three travel clinics for a YF vaccination in 2013, about 32.3% went for a booster dose that is 
no longer useful according to the revised SAGE recommendations. A drop in vaccination 
activity has to be expected by travel clinics in the next years, and changes in daily exercise 
have to be anticipated, as YF vaccination is a large part of the regular work of many 
healthcare providers specialized in travel medicine[66]. 
 
 
Vaccine shortage and fractional YF vaccines 
Vaccine shortages for YF vaccine supply that affect travelers recur on a frequent basis[67], 
the most recent in North America due to a change in manufacturing in the US. Sanofi Pasteur, 
the manufacturer of the only yellow fever vaccine (YF-VAX) licensed in the US, announced 
that their stock of YF-VAX is totally depleted as of July 24, 2017. YF-VAX for civilian use 
will be unavailable for ordering from Sanofi Pasteur until mid-2018, when their new 
manufacturing facility is expected to be completed. However, YF-VAX might be available at 
some clinics for several months, until remaining supplies at those sites are exhausted. In 
anticipation of this temporary total depletion, in 2016, Sanofi Pasteur submitted an expanded 
access investigational new drug application to the Food and Drug Administration to allow for 
importation and use of Stamaril, the YF vaccine manufactured by Sanofi Pasteur in 
France[68]. Vaccine shortages in Western countries have also led to increasing uptake of 
fractional YF vaccines in travelers[69] despite the fact that such use is currently only WHO-
endorsed in endemic populations for outbreak use. 
 
Fractional Yellow Fever vaccine 
All YF vaccines are all highly potent, with average doses between 10,00 and 44,000 
international units (IU) — far above the WHO’s recommended minimum of 1000 IU[70]. In 
principle, the quantity of vaccine virus in fractional doses of standard vaccine would therefore 
still exceed the WHO’s minimum requirement[70]. Based on this observation, WHO 
endorsed the use of 1/5 of the standard YF dose for outbreak situations when stockpiles have 
been depleted, which happened during the YF outbreak in Angola and DRC, and now also in 
Brazil. However, the potency varies from manufacturer to manufacturer and from batch to 
batch, and in particular varies from time since vaccine formulation, and hence various 
questions need to be addressed with regards to the immunogenicity and safety at doses just 
below the 1000 IU. The extent and duration of protection of fractional doses in populations 
such as children, pregnant women, persons with HIV and other co-morbidities that may result 
in different vaccine responses are currently unknown. The first study on 1/5th dose in children 
two years of age was conducted in DRC after the emergency roll-out of fractional doses, and 
reassuringly showed high seroconversion rates one month following SC 
administration[71].The results of studies comparing seroconversion rates after fractional-dose 
versus full-dose YF vaccination for each WHO-prequalified vaccine product 
(ClinicalTrials.gov number, NCT02991495), including in special populations such as children 
and persons living with HIV, are now much awaited[72]. Until those questions have been 
addressed, fractional YF vaccination is not yet compliant with the International Health 
Regulations. Should fractional YF vaccination be indeed equivalent to the standard dose, then 
the lower dose could become an antigen-sparing strategy of much broader utility[72].  
 
International Health Regulations and Yellow Fever 
Yellow fever is the only disease for which the WHO International Health Regulations (IHR) 
mandate proof of vaccination for travelers from countries where yellow fever is endemic to 
countries vulnerable for yellow fever, defined as the presence of suitable vectors[73]. An 
International Certificate of vaccination and prophylaxis (also commonly called Yellow card) 
is valid for a lifetime. Unfortunately, the 11 cases of exportation of YF via unvaccinated 
Chinese workers from Angola to China in 2016 show that the IHR regulations can be 
circumvented[74]. In fact, modelling studies show that none of the approximately 250,000 
Chinese workers in Angola at the time of the YF outbreak were vaccinated[75].  
Media reports of counterfeit markets abound. Yet, there is surprisingly little academic 
literature documenting the extent of this problem. Checks at airports and land crossing points 
appear to be non-systematic. In a study in Tanzania, checks were also performed in travelers 
who did not enter Tanzania from a YF-endemic country. No seasonal or daytime pattern 
could be identified; the thoroughness of checks varied widely. In the case of travel without 
valid YFV, an exemption certificate was always accepted[76]. It is of utmost urgency that 
governments turn their attention to enforcing the IHR.  
 
Yellow fever risk in Asia 
For travelers not complying with the IHR regulations, importation of the virus by a viremic 
traveler could initiate an enzootic transmission cycle, leading to a long-term infection risk for 
the local population. Although solid data on the extent of IHR circumvention is not available, 
it is likely that the 11 cases of importation from Angola to China will not remain the only 
cases. Why outbreaks of yellow fever have not yet occurred in Asia is unknown. The 11 cases 
were imported in China`s winter, hence vectorial capacity of Aedes mosquitoes was low[77]. 
Aedes aegypti, the more efficient vector than Aedes albopictus, does not exist in most parts of 
Europe, and hence Europe and largely the United States are less at risk, but it is not a zero 
risk, as YF outbreaks did occur in the Western hemisphere in the past[78]. With changing 
climate conditions, such a risk may increase[79, 80], further compounded by the fact that 
recently outbreaks have occurred around urban centers[81]. Is Asia prepared for a yellow 
fever epidemic?  Competent vectors exist, but some cross-protection through Asia`s highly 
prevalent dengue seroprevalence exists[82]. Provided the relative vector competence is above 
0.7, one infected traveler can introduce urban YF in a dengue endemic area beyond the 
current risk areas, as long as Aedes aegypti is present[83]. More studies are needed to 
understand the vectorial capacity and vector competence of Aedes aegypti in Asia. 
Furthermore, a better risk assessment is urgently needed for YF establishment in Asia. 
Strengthening of laboratory-based surveillance capable of detecting imported yellow fever, 
capacity to rapidly import vaccines should YF get established, and training healthcare 
workers in clinical management of severe yellow fever need to be urgently implemented[11, 
84]. 
 
Pre-Travel advice:  
YF vaccine is currently recommended for travel to 42 countries where YF is currently 
reported, or was reported in the past and where vectors/reservoirs remain. Risk assessment for 
travelers is a challenge and an evidence based GRADE approach is needed[85], in particular 
for low incidence but high impact diseases such as YF. The risk of vaccine adverse reactions 
have to be balanced against the risk of acquiring a disease with a high case fatality rate. The 
most common adverse reactions are similar to other live attenuated vaccines and include 
localized reactions, fever, headache, asthenia, malaise and myalgia, that are very common and 
generally mild and occur within one week of vaccination. No evidence exists to suggest that 
the reporting rates of allergic reactions is higher compared to other egg-derived vaccines. 
Viscerotropic and neurotropic reactions are the unique serious risks that need to be carefully 
explained to all travelers. All cases have been in primary vaccinees, and should therefore not 
occur with booster doses. Viscerotropic disease has a rapid onset, with rapid clinical 
deterioration within 7 days and a fatality in reported cases up to 50%, usually within 10 days.  
Risk factors include older age, autoimmune disease, thymectomy for thymoma, systemic 
lupus erythematosus and pernicious anemia[86]. No clear risk factors have been recognized 
for neurotropic reactions, except for very young age.  
It is very important to include travelers in the decision making process. Most travelers agreed 
they needed to understand destination-specific YF risks (82%) and vaccine risks (88%), and 
wanted to be involved in YF vaccine decisions (87%)[87]. The majority of registered travel 
agencies in Peru did not provide sufficient and accurate information regarding risk and 
prevention of YF to travelers[88]. Providers need effective risk communication skills and the 
ability to elicit and respond to travelers' concerns to help them make informed, shared 
decisions. For YF vaccines, this is particularly challenging given the uncertainties of true risk 
at destination versus YF vaccine associated adverse events.  The risk is often unpredictable 
and variable for an individual person, and cannot be quantified with any certainty in real time 
given that new emergence of outbreaks can often also not be predicted. For example, the 
recent YF outbreak in Brazil occurred in a metropolitan area that was not really predicted, and 
required ad-hoc change in recommendations[89]. It is also important that travel medicine 
providers are not falsely reassured by the absence of YF case reports in certain destinations, 
as the absence of cases could reflect good vaccine coverage rather than absence of YF virus 
transmission[90]. Travel medicine practitioners need to ensure that there is indeed an 
indication for YF vaccination, and weigh up the risk of adverse events versus individual risk 
of acquiring YF during travel, dependent on duration, outbreak intensity, and activities during 
travel. For persons older than 60, and clearly for all persons with a history of thymus disease, 
a medical certificate should be issued stating that such travelers are exempt from vaccination. 
Travel medicine practitioners need to advise on alternative risk management measures 
including personal protective measures to avoid mosquito bites although compliance rates are 
notoriously low[91-93]. 
 
Conclusions:  
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